Caspase-9 is involved in the intrinsic apoptotic pathway and suggested to play a role as a
tumor suppressor. Little is known about the mechanisms governing
caspase-9 expression, but post-transcriptional
pre-mRNA processing generates 2 splice variants from the
caspase-9 gene, pro-apoptotic caspase-9a and anti-apoptotic caspase-9b. Here we demonstrate that the ratio of
caspase-9 splice variants is dysregulated in
non-small cell lung cancer (NSCLC)
tumors. Mechanistic analysis revealed that an exonic splicing silencer (ESS) regulated
caspase-9 pre-mRNA processing in NSCLC cells.
Heterogeneous nuclear ribonucleoprotein L (
hnRNP L) interacted with this ESS, and downregulation of
hnRNP L expression induced an increase in the
caspase-9a/9b ratio. Although expression of
hnRNP L lowered the
caspase-9a/9b ratio in NSCLC cells, expression of
hnRNP L produced the opposite effect in non-transformed cells, suggesting a post-translational modification specific for NSCLC cells. Indeed, Ser52 was identified as a critical modification regulating the
caspase-9a/9b ratio. Importantly, in a mouse xenograft model, downregulation of
hnRNP L in NSCLC cells induced a complete loss of tumorigenic capacity that was due to the changes in
caspase-9 pre-mRNA processing. This study therefore identifies a
cancer-specific mechanism of
hnRNP L phosphorylation and subsequent lowering of the
caspase-9a/9b ratio, which is required for the tumorigenic capacity of NSCLC cells.